Thyroid News and Research

RSS

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease.

28 Oct 2015

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

A discovery made by investigators from Beth Israel Deaconess Medical Center and the Boston University School of Medicine may help lead to the development of a cell-based regenerative therapy which could be used to restore thyroid function in patients with cancer who have had their thyroids surgically removed and children born with congenital hypothyroidism.

23 Oct 2015

Nagoya University professor receives 2015 Van Meter Award for thyroid research

Takashi Yoshimura, a professor at the Institute of Transformative Bio-Molecules at Nagoya University in Japan, has won the 2015 Van Meter Award for his contributions to thyroid research.

23 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Latest research on thyroid cancer to be highlighted at 15th International Thyroid Congress

The effect of radiation exposure related to the nuclear accidents that took place in Fukushima, Japan, and Chernobyl, Ukraine on thyroid cancer risk, whether dietary habits influence the risk of developing thyroid cancer, and recent study results with a triiodothyronine (T3) analog in an uncommon form of thyroid disease are all topics featured in oral presentations delivered at the 15th International Thyroid Congress, hosted by the American Thyroid Association, October 18-23, 2015, in Orlando, Florida.

19 Oct 2015

New ATA guidelines for managing adult patients with thyroid nodules and DTC published in Thyroid journal

New, evidence-based recommendations from the American Thyroid Association will help guide clinicians in managing patients with thyroid nodules, a common disorder that requires evaluation to distinguish benign nodules from malignancy, interpret biopsy results and molecular marker studies, and initiate risk assessment and cancer screening.

15 Oct 2015

Thyroid hormone treatment improves cardiac health in female rats with high blood pressure

Thyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.

14 Oct 2015

Clinical study results of VolitionRx's NuQ test for pancreatic cancer published in Clinical Epigenetics

VolitionRx Limited today announced that full results from a completed clinical study of its NuQ blood-based test for early stage pancreatic cancers have been published in the online issue of Clinical Epigenetics, the official journal of the Clinical Epigenetics Society.

14 Oct 2015

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx immunohistochemistry test, available through Dako, an Agilent Technologies company.

From Quest Diagnostics 13 Oct 2015

ATA announces research grants to support projects proposed by young researchers

The American Thyroid Association is pleased to announce that grants have been awarded to support projects proposed by leading young researchers. Three of these projects involve the genetic analysis of thyroid tumors carrying the BRAFV600E mutation, which is associated with the development of some forms of thyroid cancer and increased risk for distant metastases, more advanced disease, and higher mortality.

13 Oct 2015

ATA announces first-year research grants to support promising young researchers

The American Thyroid Association (ATA) is pleased to announce the awarding of first-year grants to support two young researchers selected from among a pool of applicants who proposed projects that will contribute novel insights and information with the potential to lead to new drug targets and therapeutic strategies to improve the treatment of thyroid cancer and patient outcomes.

13 Oct 2015

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it.

12 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Endocrine-disrupting chemical exposure linked to increased risk of diabetes and obesity

Emerging evidence ties endocrine-disrupting chemical exposure to two of the biggest public health threats facing society - diabetes and obesity, according to the executive summary of an upcoming Scientific Statement issued today by the Endocrine Society.

29 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

New computational model may help overcome misalignment of U.S. biomedical research resources

A new computational model developed by scientists from the University of Chicago could help improve the allocation of U.S. biomedical research resources.

16 Sep 2015

ICU-related mortality may explain variations in cancer outcomes

A Scottish population-based study has characterised the incidence of critical illness resulting in admission to an intensive care unit during the first 2 years after a cancer diagnosis.

9 Sep 2015

Latest ENT research to be presented at AAO-HNSF's annual meeting

The latest research on hearing loss, head and neck cancers, sleep apnea and other otolaryngic topics will be presented in Dallas, TX, September 27-30, at the 2015 Annual Meeting & OTO EXPO? of the American Academy of Otolaryngology--Head and Neck Surgery Foundation (AAO-HNSF), the largest annual meeting of ear, nose, throat, head and neck physicians in the world.